Biocon arm features in Asia IP Elite list

Hyderabad Biocon Biologics Limited, a subsidiary of Bengaluru based Biocon Limited on Friday announced that the company has featured on the Asia IP Elite list for 2022 by Intellectual Asset Management (IAM). Biocon is recognised for its Intellectual Property (IP) management and IP value creation in the Asia-Pacific region.

Biocon Biologics' IP team was honoured at the latest edition of the IP Business Congress Asia, which is hosted by Intellectual Asset Management (IAM), the publishers of the leading IP magazine, IAM. 80 organisations from the Asia-Pacific regions featured in this year's event, which was organised after a gap of two years.

Biocon stated it was the first and only pharmaceutical company from India to be featured on the Asia IP Elite list in 2016. Biocon Biologics debuted on the list in 2019. This is the fifth consecutive year that a Biocon Group company has made it to the Asia IP Elite list. IAM recognises companies across the Asia-Pacific regions that demonstrate a sustained commitment to building best-in-class in-house IP functions and continuous excellence in IP value creation.

Shreehas Tambe, deputy CEO, Biocon Biologics said, "This recognition is an endorsement of the Biocon Group's commitment towards innovation and value creation for its stakeholders. Biocon and its subsidiaries have a strong track record of generating IP with over 1,000 granted patents for biologics till date."

Biocon Biologics is leveraging its robust in-house Intellectual Property (IP) strategy and capabilities to enable early entry of biosimilar products to meet patient needs in global markets, Tambe further added.